Karyopharm Therapeutics Inc
$ 7.47
-21.45%
20 Jul - close price
- Market Cap 215,525,000 USD
- Current Price $ 7.47
- High / Low $ 9.45 / 6.49
- Stock P/E N/A
- Book Value -11.78
- EPS -16.40
- Next Earning Report 2026-08-10
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.41 %
- ROE -8.91 %
- 52 Week High 10.99
- 52 Week Low 3.65
About
Karyopharm Therapeutics Inc., a pharmaceutical company, is dedicated to the discovery, development and commercialization of various drugs directed against nuclear export and related targets for the treatment of cancer and other diseases. The company is headquartered in Newton, Massachusetts.
Analyst Target Price
$13.50
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-14 | 2026-02-12 | 2025-11-03 | 2025-08-11 | 2025-05-12 | 2025-02-19 | 2024-11-05 | 2024-08-06 | 2024-05-08 | 2024-02-29 | 2023-11-02 | 2023-08-02 |
| Reported EPS | -1.24 | -2.23 | -3.82 | -4.07 | -2.77 | -3.6 | -3.9 | -4.34 | -4.8 | -0.36 | -4.5 | -4.35 |
| Estimated EPS | -1.44 | -2 | -3.25 | -3.91 | -3.09 | -4.03 | -3.92 | -4.47 | -4.94 | -0.31 | -4.29 | -5.04 |
| Surprise | 0.2 | -0.23 | -0.57 | -0.16 | 0.32 | 0.43 | 0.02 | 0.13 | 0.14 | -0.05 | -0.21 | 0.69 |
| Surprise Percentage | 13.8889% | -11.5% | -17.5385% | -4.0921% | 10.356% | 10.67% | 0.5102% | 2.9083% | 2.834% | -16.129% | -4.8951% | 13.6905% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-10 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -1.25 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: KPTI
2026-07-19 04:40:01
Karyopharm Therapeutics presented at the Jefferies Global Healthcare Conference 2026, highlighting progress with its lead compound, selinexor (XPOVIO). Key updates included significant improvements in spleen volume reduction and early overall survival signals from the Phase III SENTRY trial in myelofibrosis, and the completion of enrollment for the EC-042 phase III endometrial cancer trial. The company anticipates regulatory clarity within 1-2 quarters and has a cash runway extending to late Q3.
2026-07-18 12:10:38
Karyopharm Therapeutics Inc. has implemented a 2026 Leadership Cash Retention Program for its key executives, including named executive officers and the CFO, to incentivize their retention during an anticipated period of significant corporate milestones. This program replaces the annual bonus plan for 2026 and involves one-time lump sum cash awards, with repayment provisions if employment terminates under certain conditions. The initiative signals upcoming sensitive corporate events and aims to ensure leadership continuity, potentially impacting the company's share price.
2026-07-17 23:10:38
Karyopharm Therapeutics (KPTI) shares declined by 2.6% after the company disclosed that it would be providing a cash retention program for its executives. The program, designed to incentivize continued employment despite "headwinds" in the biotech sector and to support "key strategic initiatives," will grant six executives cash bonuses ranging from $130,000 to $400,000, payable in two installments. CEO Richard Paulson is also eligible for an additional bonus of up to $1.2 million.
2026-07-17 21:10:18
Karyopharm Therapeutics Inc. (NASDAQ: KPTI) has established a 2026 Leadership Cash Retention Program on July 13, 2026, to ensure the retention of key executives, including its named executive officers and CFO, during a period of anticipated significant catalysts. This program replaces guaranteed amounts from the company's 2026 Annual Bonus Plan, providing lump-sum cash awards to four executives ranging from $625,000 to $1,725,000. These awards may be subject to repayment if employment terminates under certain conditions within a specified timeframe, and they will reduce any amounts payable under existing severance arrangements.
2026-07-14 03:11:42
This article provides a bond risk profile for Karyopharm Therapeutics Inc.'s 6.0% bond, KPTI5813817, due May 13, 2029. It highlights key metrics for credit risk assessment, including security level, inflation protection, and issuer rating, to help investors evaluate reliability. The platform, TradingView, offers this data along with exclusive analyst ratings.
2026-07-13 21:42:03
This article provides a bond profile for Karyopharm Therapeutics Inc.'s KPTI5813817 bond, detailing key metrics such as a 6.0% coupon rate and a May 13, 2029 maturity date. The company, founded in 2008, is a commercial-stage pharmaceutical company focused on cancer and other diseases. The profile also highlights an outstanding amount of 541.00K USD and a face value of 1,000.00 USD.
